Prothena Corporation (PRTA)

DUBLIN--(BUSINESS WIRE)--Prothena announced that the Company has initiated an approximate 63% reduction in its workforce.

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson's disease.

PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.

Prothena Corporation plc PRTA released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis on Friday.

DUBLIN--(BUSINESS WIRE)--Prothena today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint.

PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Prothena (PRTA) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $1.34 per share a year ago.

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today reported financial results for the first quarter of 2025 and provided business highlights.

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025.